Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Semafor and Gizmodo. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 77d ago.
Quick answers
Why is "Kalshi comes for biopharma, with prediction markets for clinical trials and FDA " trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Kalshi bets on Wall Street Semafor · 91d ago
- Kalshi Is Set to Start Taking Bets on Drug Trials Gizmodo · 91d ago
Topics
Related trends
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
The FDA approves a once-daily Parkinson's pill, marking the first new drug class in half a century.
People say these peptides hurt them. Their stories are muffled in MAHA’s push for medical freedom
Adverse events tied to gray market peptides spark safety warnings while clashing with medical freedom pushes.
FDA’s New Leadership Aims to Overhaul Rare Disease Approvals
FDA’s new Rare Disease Framework Initiative seeks to modernize approvals for therapies targeting ultra‑small patient groups.
Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
How to bet Bills-Rams on MNF: Analysis, tips and top prop plays
Betting buzz spikes as the Bills take on the Rams on Monday Night Football, with promo codes and prop tips flooding sports sites.
Baby sleep product recalled after FDA finds 3 types of alcohol not listed on label
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.